Epidemiology of Respiratory Syncytial Virus Infection in Preterm Infants
Open Access
- 30 December 2011
- journal article
- Published by Bentham Science Publishers Ltd. in The Open Microbiology Journal
- Vol. 5 (1), 135-143
- https://doi.org/10.2174/1874285801105010135
Abstract
This review focuses on the burden of respiratory syncytial virus (RSV) infection in preterm infants with and without chronic lung disease (bronchopulmonary dysplasia, BPD). The year-to-year and seasonal variations in RSV activity are key aspects of RSV epidemiology, and knowledge/monitoring of local RSV activity is mandatory for guidance of prophylaxis with the monoclonal antibodies palivizumab and in the near future motavizumab. Morbidity expressed in rates of hospitalizations attributable to RSV illness revealed a mean of 10 percent in preterm infants without and 19 percent (p=0.016) with BPD. Mortality rates diverged widely, and case fatality rates have been reported to range from 0 to 12 percent. The typical clinical picture of lower respiratory tract infection is not different in term and preterm infants, but rates of apnoeas are significantly increased in preterms, ranging from 4.9 to 37.5 percent with decreasing rates observed in more recent studies. Until a RSV vaccine is developed and will be available, prophylaxis with palivizumab is the only preventative strategy other than hand hygiene and contact measures that significantly reduces RSV hospitalization rates in preterm infants both with and without BPD.Keywords
This publication has 73 references indexed in Scilit:
- POPULATION BASED EXTERNAL VALIDATION OF A EUROPEAN PREDICTIVE MODEL FOR RESPIRATORY SYNCYTIAL VIRUS HOSPITALIZATION OF PREMATURE INFANTS BORN 33 TO 35 WEEKS OF GESTATIONAL AGEThe Pediatric Infectious Disease Journal, 2010
- Incidence of Apnea in Infants Hospitalized with Respiratory Syncytial Virus Bronchiolitis: A Systematic ReviewThe Journal of Pediatrics, 2009
- A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33–35 weeks of gestational age, based on data from the Spanish FLIP studyRespiratory Research, 2008
- Palivizumab Use in Very Premature Infants in the Neonatal Intensive Care UnitPEDIATRICS, 2004
- Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infantsThe Pediatric Infectious Disease Journal, 2003
- Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: Results from the palivizumab outcomes registryPediatric Pulmonology, 2003
- Respiratory syncytial virus epidemics: the ups and downs of a seasonal virusThe Pediatric Infectious Disease Journal, 2003
- Respiratory syncytial virus infectionThe Lancet, 1999
- Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infectionThe Journal of Pediatrics, 1995
- Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian childrenThe Journal of Pediatrics, 1992